DMTF1 is a novel tumor suppressor that receives signals from oncogenic RAS and activates the ARF -P53 pathway. D-type cyclins antagonize the activity of Dmtf1 when E2F sites are not on the promoter; however, they synergize with Dmtf1 on the Arf promoter. Recent study shows significant involvement of DMTF1 in human non-small-cell lung carcinomas.
Expression
Mouse Dmtf1 protein is expressed in the testis, thymus, spleen, brain, lung, and kidney.
Localisation
Both human and mouse DMTF1 alpha proteins are localized in the nucleus.
Function
Dmtf1-null mice are prone to spontaneous tumor development, which was accelerated when the animals were neonatally treated with ionizing radiation or dimethylbenzanthracene.
Lung adenomas/adenocarcinomas were the most common tumors found in Dmtf1-deficient mice. Eµ-Mycinduced lymphomagenesis was significantly accelerated in Dmtf1-deficient mice. The retention and expression of the wild-type Dmtf1 allele in tumors arising in heterozygotes indicated that Dmtf1 is haploinsufficient for tumor suppression. The low frequency of Arf deletion and p53 mutation in tumors from Dmtf1-knockout mice suggested that Dmtf1 is a physiological regulator of the Arf-p53 pathway in vivo. The DMTF1 promoter is activated by the oncogenic RAS -RAF -MEK -ERK -JUN pathway, and the induction of ARF by RAS is DMTF1-dependent. Thus, DMTF1 is a critical mediator of p19ARF in response to oncogenic RAS signaling. The importance of dmp1 in P53 regulation was recently demonstrated by crossing Dmtf1-deficient mice with K-ras LA transgenic mice. The Dmtf1 promoter is repressed by overexpression of E2Fs and also by physiological mitogenic signaling. Thus, DMTF1 is a marker of cells that have exited from the cell cycle. The DMTF1 promoter is repressed by genotoxic stimuli mediated by NF-kappa B, and repression of the ARF promoter by genotoxic stimuli is DMP1-dependent. Very little studies have been conducted on the post-translational modifications for DMTF1. 
Homology

Implicated in
Non-small-cell lung carcinoma Disease One report shows that loss of heterozygosity (LOH) for the human DMTF1 gene was found in around 35 % of human non-small-cell lung cancers, especially those without deletions or methylation of p14ARF and/or 
